Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actelion Pharmaceuticals Ltd.

Division of Johnson & Johnson
www1.actelion.com

Latest From Actelion Pharmaceuticals Ltd.

Co-Pay Charity Settles Charges It Conspired With Teva, Biogen, Novartis On Kickbacks

The Assistance Fund directed donations received from the companies to patients taking their multiple sclerosis drugs, the US Department of Justice announced. Further settlements may be pending.

Compliance Legal Issues

Novartis’s Fevipiprant Hit By Phase III Asthma Failure

Novartis’s investigational oral therapy for asthma fell at the first Phase III hurdle but pivotal studies in severe disease will be key to prospects.

Respiratory Clinical Trials

From Rare To Real: Pharma Urged To Act As China Preps New Rare Conditions List

Chinese regulatory agency working around the clock in preparation to release another official list of rare diseases, and a push to launch more innovative orphan drugs is underway. But this time pharma firms need to be more proactive, noted an NMPA official.

China Rare Diseases

Novartis Makes Mayzent Case With More MS Data

Presentations at ECTRIMS highlight the recently approved pill's effects on disability and cognition.

 

Neurology Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register